Our expert introduces some of the bioprocessing best practices required to de-risk the commercial manufacturing of cell and gene therapies. Watch our webinar to learn:
- the principles of commercialization readiness, logical steps and the best practices to address them in process development
- FMEA (failure mode and effects analysis) and how to use it for commercialization readiness
- the best time to implement automation and minimize the commercialization risks
- the key requirements for analytical methods used in the commercial processes
Spear: Dr Behnam Ahmadian Baghbaderani, Global Head of Process Development for Cell & Gene Technologies